On the afternoon of March 29, the Boao Forum for Asia (BFA) 2024 Annual Conference came to an end. During the four-day conference, nearly 2,000 Chinese and foreign guests from more than 60 countries and regions focused on the theme of "Asia and the World: Common Challenges, Common Responsibilities", exchanged views on the world economy, scientific and technological innovation, social development, international cooperation and other issues, and discussed the propositions of the times together.

Dr. Xuefeng Yu, Chairman and CEO of CanSinoBio, was invited to attend the forum and discussed with more than 20 medical and health experts, industry think tanks and representatives of innovative enterprises from China, the United Arab Emirates, Kenya, Nigeria, South Africa, Singapore, and India on the theme of "Health without Borders - International Medical and Healthcare Cooperation. Through the development of new quality productivity, strengthen the global cooperation to eliminate health disparities and promote global health equity.

Dr. Yu Xuefeng said that the development of new quality productivity has become the focus and hotspot of widespread concern in the whole society, and the biomedical industry is an important part of the new quality productivity, and adherence to innovation is the key.

CanSinoBio has constructed five major technology platforms and formed a highly competitive product pipeline, including a number of innovative vaccine products targeting the prevention of more than 10 indications, such as meningitis, pneumonia, pertussis, neocoronavirus pneumonia, Ebola virus disease, herpes zoster, and tuberculosis, etc. Among them, the first tetravalent rheumatoid conjugate vaccine in Asia, developed by the company, has achieved a stage-by-stage commercialization success.

Regarding the promotion of sustainable development of global healthcare, Dr. Yu said, CanSinoBio is committed to "bringing innovative, high-quality and accessible vaccines to the world", and insists on adopting the world's leading technology and international standard quality management and control system, and taking every step from research and development, clinic to industrialization and commercialization. This is our commitment to innovation and entrepreneurship. This is our commitment to innovation and entrepreneurship, as well as the original intention that we have adhered to for the past 15 years.

In addition, CanSinoBio joins hands with outstanding experts and scholars around the world to provide objective and professional strategic guidance and advice on the science and feasibility of the company's major resource integration projects.

In 2017, the company developed the only Ebola virus disease vaccine in Asia, which first emerged to the world. In recent years, with the support of many parties in terms of policy, regulation and market access in various countries, CanSinoBio has established communication with a number of international organizations and overseas institutions to promote cooperation between China and other emerging markets in the field of global medical innovation.

In the past year, CanSinoBio signed a Memorandum of Understanding (MOU) on vaccines with the Ministry of Health of Indonesia, Tsinghua University, and Etana, an Indonesian biopharmaceutical company, to build a technical platform for vaccine evaluation, and signed a framework agreement on vaccine cooperation with SPIMACO, a Saudi Arabian pharmaceutical manufacturing company, to enter the Saudi Arabian and other MENA markets, using a rheumatoid vaccine product as a starting point.

In addition, CanSinoBio signed a project funding agreement with the Bill & Melinda Gates Foundation to support the development of the Company's virus-like particle-based polio vaccine, VLP-Polio, and signed a Product Supply Collaboration Framework Agreement with AstraZeneca, focusing on utilizing the Company's mRNA production platform to support its research and development of specific vaccines. These collaborations affirm CanSinoBio's R&D strength and competitive advantages in VLP assembly technology and mRNA technology platform.

During the conference, Dr. Yu was interviewed exclusively by Bloomberg TV, the world's leading financial and monetary information platform, on the company's continued rapid progress in the development of several vaccine candidates.

Dr. Yu said CanSinoBio is ready to meet the opportunities and challenges of the new development landscape and to empower high-quality development through a higher level of openness and international cooperation.

As a global vaccine supplier rooted in China, CanSinoBio will always adhere to the concept of "More than Innovation, No Disease in the World", adhere to the new quality productivity, continue to develop in high quality, and work together with various partners to contribute more to the high-quality development of the health industry.

https://mp.weixin.qq.com/s?__biz=MzI0Nzc5MDU4OQ==&mid=2247494893&idx=1&sn=788c6f8b9a230e259b131d2f64ecc322&chksm=e9a8027fdedf8b691f93eeb23d413f23e3882bb7937b05628ef44ab4181b30dcf3fdde814d31&mpshare=1&scene=1&srcid=0403dN2xySlEU6wbhJ2kfnkA&sharer_shareinfo=5bfc7c2d6667c4a29c0a1fbc6945e68a&sharer_shareinfo_first=5bfc7c2d6667c4a29c0a1fbc6945e68a#rd